Medpace Holdings, Inc. $MEDP Stock Position Reduced by Alpine Peaks Capital LP

Posted by George Bondi on Jun 18th, 2026

Alpine Peaks Capital LP lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 25.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,506 shares of the company’s stock after selling 3,200 shares during the quarter. Medpace makes up about 5.1% of Alpine Peaks Capital LP’s holdings, making the stock its 8th largest position. Alpine Peaks Capital LP’s holdings in Medpace were worth $5,339,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Guggenheim Capital LLC increased its holdings in Medpace by 43.9% in the fourth quarter. Guggenheim Capital LLC now owns 4,263 shares of the company’s stock valued at $2,394,000 after buying an additional 1,301 shares during the last quarter. Caisse de depot et placement du Quebec increased its holdings in Medpace by 23.0% in the fourth quarter. Caisse de depot et placement du Quebec now owns 80,218 shares of the company’s stock valued at $45,054,000 after buying an additional 14,975 shares during the last quarter. AQR Capital Management LLC increased its holdings in Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares during the last quarter. Abel Hall LLC purchased a new position in Medpace in the fourth quarter valued at $202,000. Finally, Cetera Investment Advisers increased its holdings in Medpace by 30.1% in the fourth quarter. Cetera Investment Advisers now owns 20,070 shares of the company’s stock valued at $11,272,000 after buying an additional 4,649 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 1.0%

NASDAQ MEDP opened at $457.09 on Thursday. Medpace Holdings, Inc. has a 52-week low of $294.07 and a 52-week high of $628.92. The business’s 50-day moving average price is $454.30 and its 200 day moving average price is $500.75. The firm has a market cap of $13.05 billion, a P/E ratio of 28.73, a P/E/G ratio of 2.34 and a beta of 1.18.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter last year, the company posted $3.67 earnings per share. The business’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Barclays dropped their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a report on Friday, April 24th. Robert W. Baird dropped their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and dropped their target price for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Royal Bank Of Canada dropped their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus price target of $467.08.

Check Out Our Latest Research Report on MEDP

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.